Clinical Trial SuccessPlozasiran treatment led to a statistically significant reduction in incidence of acute pancreatitis vs. placebo, a key secondary endpoint and a major potential differentiator.
Drug ApprovalPlozasiran poised to become Arrowhead's first marketed drug, potentially in 2025.
Research And DevelopmentArrowhead's targeted RNAi molecule (TRiM) platform enables delivery of small interfering RNA (siRNA) to the lung via aerosol inhalation, representing important progress of RNAi therapeutics outside the liver and into pulmonary diseases.